Social Determinants of Health Simulation

By João L. Carapinha

November 1, 2023

PhRMA’s Social Determinants of Health

Let’s look into an insightful article by Kristin Williams, published on October 27, 2023. The piece shines a light on the structural barriers patients encounter when trying to access and afford medicines. Community-level factors strongly impact healthcare access, the research shows. Nearly 40% of US counties are pharmacy deserts! These shocking numbers highlight the difficulties many encounter in accessing drugs. The article then discusses PhRMA’s Social Determinants of Health (SDOH) simulation. This novel application lets users follow a patient’s journey and demonstrate how structural and social variables impact life-saving pharmaceutical access.

Better pharmaceutical access and adherence might save the U.S. $3.8 trillion in medical bills and lost productivity. It shows how much tackling healthcare inequality matters.

It appears that insufficient insurance coverage considerably affects care access. Though true for many, insurance alone isn’t a panacea. High out-of-pocket prices, complicated approval processes, and restricted prescription formularies are common even with coverage. Thus, while insurance is important, we must also address healthcare structural challenges.

Kristin Williams’ post challenges us to address healthcare’s structural barriers and promote a more fair system. We can create a healthy future in the US and other countries.

Reference url

Recent Posts

NICE Endorses Darolutamide Prostate Cancer Treatment for Improved Patient Access

By HEOR Staff Writer

October 24, 2025

Darolutamide prostate cancer treatment has received a major endorsement from the National Institute for Health and Care Excellence (NICE), which issued final draft guidance recommending darolutamide combined with androgen deprivation therapy (ADT) for adults with hormone-sensitive metastatic pros...
Rethinking Health Technology Assessment: Evolving Economic Evaluations for Fair Resource Allocation
Health technology assessment plays a pivotal role in resource-constrained healthcare systems. How can organizations like NICE, ICER, and Canada's Drug Agency better incorporate novel value elements into economic evaluations? They can do so by adopting a principled framework that evolves beyond tr...
FDA Cancer Trial Guidelines: Prioritizing Overall Survival for Patient-Centered Approvals

By João L. Carapinha

October 23, 2025

The FDA cancer trial guidelines from August 2025 emphasize overall survival (OS) as the key endpoint for oncology drug approvals. If you're wondering how these FDA cancer trial guidelines impact patient outcomes in treatment trials, they shift focus from surrogate measures like progression-free s...